Perifosine: Additional Phase II data

A subgroup analysis of 16 patients in a Phase II trial who failed treatment with either Nexavar sorafenib or Sutent sunitinib and either Torisel temsirolimus or Afinitor everolimus showed that 100 mg daily perifosine produced 1 partial response and 7 cases of stable disease for >12 weeks. Median PFS was 16 weeks. Perifosine was well tolerated. Data were presented at the International Kidney Cancer Symposium in Chicago. The partners previously reported data from 44 evaluable patients in which perifosine produced partial responses in 2 patients and stable disease for >12 weeks in 19 patients (see BioCentury, May 25). ...